By targeting drugs with multiple actions, such as inhibitors of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), this approach is specifically beneficial for treating Alzheimer’s disease [4]. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.